MKI67 and neoplasm: According to Spyratos et al (2002), the choice of cutoff depends on the clinical objective: if Ki-67 is used to exlude patients with slowly proliferating tumours from chemotherapeutic protocols, a cutoff of 10% will help to ovoid overtreatment.